clinical trial · NCT06472245
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
OSE Immunotherapeutics·phase3·recruiting·n = 363
Patients With Non-Small Cell Lung CancerOSE2101DocetaxelNGS HLAA2 assay
brief summary
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).
started
Dec 3, 2024
primary completion
May 1, 2028
completion
Dec 15, 2028
last updated
Nov 12, 2026
official title
A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol